vs
Side-by-side financial comparison of GCL Global Holdings Ltd (GCL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
GCL Global Holdings Ltd is the larger business by last-quarter revenue ($98.7M vs $70.6M, roughly 1.4× Viridian Therapeutics, Inc.\DE). GCL Global Holdings Ltd runs the higher net margin — -5.2% vs -49.0%, a 43.9% gap on every dollar of revenue. GCL Global Holdings Ltd produced more free cash flow last quarter ($-5.2M vs $-84.7M).
GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
GCL vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $98.7M | $70.6M |
| Net Profit | $-5.1M | $-34.6M |
| Gross Margin | 11.0% | — |
| Operating Margin | -6.7% | -56.7% |
| Net Margin | -5.2% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $98.7M | $70.6M | ||
| Q2 25 | $142.1M | — | ||
| Q3 24 | $36.1M | — |
| Q3 25 | $-5.1M | $-34.6M | ||
| Q2 25 | $5.6M | — | ||
| Q3 24 | $-1.9M | — |
| Q3 25 | 11.0% | — | ||
| Q2 25 | 15.0% | — | ||
| Q3 24 | 16.2% | — |
| Q3 25 | -6.7% | -56.7% | ||
| Q2 25 | 2.3% | — | ||
| Q3 24 | -5.6% | — |
| Q3 25 | -5.2% | -49.0% | ||
| Q2 25 | 3.9% | — | ||
| Q3 24 | -5.2% | — |
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $0.05 | — | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | $490.9M |
| Total DebtLower is stronger | $52.0M | — |
| Stockholders' EquityBook value | $33.1M | $503.0M |
| Total Assets | $159.9M | $577.1M |
| Debt / EquityLower = less leverage | 1.57× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $16.6M | $490.9M | ||
| Q2 25 | $18.2M | — | ||
| Q3 24 | $2.7M | — |
| Q3 25 | $52.0M | — | ||
| Q2 25 | $11.9M | — | ||
| Q3 24 | — | — |
| Q3 25 | $33.1M | $503.0M | ||
| Q2 25 | $35.9M | — | ||
| Q3 24 | $15.9M | — |
| Q3 25 | $159.9M | $577.1M | ||
| Q2 25 | $101.6M | — | ||
| Q3 24 | $49.6M | — |
| Q3 25 | 1.57× | — | ||
| Q2 25 | 0.33× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-84.6M |
| Free Cash FlowOCF − Capex | $-5.2M | $-84.7M |
| FCF MarginFCF / Revenue | -5.3% | -120.1% |
| Capex IntensityCapex / Revenue | 0.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.8M | $-84.6M | ||
| Q2 25 | $-10.3M | — | ||
| Q3 24 | $6.1M | — |
| Q3 25 | $-5.2M | $-84.7M | ||
| Q2 25 | $-10.5M | — | ||
| Q3 24 | — | — |
| Q3 25 | -5.3% | -120.1% | ||
| Q2 25 | -7.4% | — | ||
| Q3 24 | — | — |
| Q3 25 | 0.4% | 0.2% | ||
| Q2 25 | 0.1% | — | ||
| Q3 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | -1.84× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
